Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...
Incyte (Nasdaq: INCY) said the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback